Trial Profile
A open-label, long-term efficacy and safety of mecasermin (rhIGF-1) therapy in patients with severe primary IGF-1 deficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2015
Price :
$35
*
At a glance
- Drugs Mecasermin (Primary)
- Indications Short stature; Somatotropin deficiency
- Focus Therapeutic Use
- Sponsors Genentech; Ipsen Biopharmaceuticals
- 27 Dec 2015 New trial record